Corcept Therapeutics Inc
CORTCIK 0001088856 · last filing Jul 8, 2026
Insider signal
trades dated in the last 90 days · non-derivative only
45,000 bought / 45,600 sold
net −600 sh · −$3.43M
- buys
- 2
- sells
- 6
- insiders active
- 3
Filing tape
Filed Wed, Jul 8, 2026
- −600 sh
Robb Gary Charles — Chief Business Officer
- Gifted600Common Stock→ 25,081 heldtrade dated May 27, 2026
- −0 sh · $1.43M
Guyer William — Chief Development Officer
- Exercised20,000Common Stock@ $21.65→ 23,985 held
- Sold19,048Common Stock@ $93.11→ 4,937 held
- Sold952Common Stock@ $93.54→ 3,985 held
- Exercised20,000Stock Option (right to buy)→ 130,000 held
Filed Mon, Jul 6, 2026
- −0 sh · $2.00M
Maduck Sean — See Remarks
- Exercised25,000Common Stock@ $8.27→ 34,755 held
- Sold11,024Common Stock@ $87.33→ 23,731 held
- Sold2,801Common Stock@ $88.51→ 20,930 held
- Sold11,175Common Stock@ $89.31→ 9,755 held
- Exercised25,000Stock option (right to buy)→ 116,986 held
Insiders on this tape
- Robb Gary CharlesChief Business Officer
- Guyer WilliamChief Development Officer
- Maduck SeanSee Remarks
Informational data only — not investment advice.
The institutional holdings shown here are aggregated from third-party public regulatory filings (such as SEC Form 13F). These filings are reported with a delay (generally up to 45 days after each quarter-end), are backward-looking, and may exclude short positions, non-U.S. holdings, cash, and other assets. The data may contain errors, omissions, misclassifications, or gaps, and may not reflect a manager's current positions.
All figures are provided on an "as is" basis for general information only. Nothing on this page is financial, investment, or trading advice, a recommendation, or an endorsement of any security, manager, or strategy. Do not rely on it. Independently verify any figure against the original filings and consult a qualified professional before making any financial decision. Your use is subject to our Terms of Service.